Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Wants To Join The Biosimilars Party, In Time

Executive Summary

India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.

You may also be interested in...



Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success

South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.

Henlius Capitalizes On Biosimilar Launches

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

Sun Has ‘Great Expectations’ For Ilumya In Japan

Sun is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola. The IL-23p19 inhibitor is also among the Indian firm's specialty products that saw US sales claw back to pre-COVID levels in Q2.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel